It is commonly believed that antibodies are too large (∼ 150 kDa) to access the intracellular
compartment. Therefore, therapeutic antibodies have been traditionally used to target cell …

The rollercoaster ride to anti-cancer antibodies | Nature Biotechnology Skip to main content
Thank you for visiting nature.com. You are using a browser version with limited support for …

Monoclonal antibodies (mAbs) targeting antigens expressed at the surface of tumor cells are
widely used for cancer control in clinics, but these treatments need to be improved. Chew et …

Protein kinases play a critical regulatory role in essentially every aspect of cell biology. Of
the 518 known kinases, the most successful class for drug targeting is the receptor tyrosine …

Background: The clinical efficacy of mAbs is generally ascribed to interference with signaling
pathways leading to arrest of cell-cycle progression and inhibition of tumor growth …

Following Milstein's discovery, the monoclonal antibodies (mAbs) became a basic tool for
biomedical science. In cancer field, since the first mAb was approved by the FDA a great …

Cancer is the second leading cause of death in the United States with one of every four
deaths attributable to cancer (Jemal et al. 2006). The first references to cancer date back to …

In recent decades, there has been a surge in the approval of monoclonal antibodies for
treating a wide range of hematological and solid malignancies. These antibodies exhibit …

The recent approval of cetuximab and bevacizumab by FDA for the treatment of metastatic
colorectal cancer witnesses the investments of biotech companies in the development of …